Arkolith/Insider Trading/SABS/Form 4

Moin Andrew

DirectorSAB Biotherapeutics, Inc. (SABS) · full profile →Form 4 · filed Oct 24, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
0 non-derivative · 2 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 23, 2023Grant(A)16K$1000.00$16.3M18K
Oct 23, 2023Option exercise(M)16K——0

Transaction Codes

A
Grant / award
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-23-054936) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML